{"gene":"FLII","run_date":"2026-04-28T17:46:03","timeline":{"discoveries":[{"year":2006,"finding":"Flightless-I (Fli-I/FLII) functions as a coactivator for nuclear receptor-mediated transcription and inhibits beta-catenin/LEF1/TCF-dependent transcription. Fli-I was found to disrupt the synergy between FLAP1 (Fli-I leucine rich repeat associated protein 1), p300, and beta-catenin, thereby suppressing Wnt target gene activation. FLAP1 directly interacted with beta-catenin, GRIP1, and p300 and enhanced their transcriptional activity, while Fli-I counteracted this. The opposing activities of Fli-I and FLAP1 were proposed as a regulatory mechanism for Wnt/beta-catenin signaling, with Fli-I mutations potentially causing developmental defects (e.g., Drosophila flightless phenotype) through dysregulation of this pathway.","method":"Transient transfection reporter assays, co-immunoprecipitation, GST pull-down, siRNA knockdown of endogenous FLAP1","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 2-3 — multiple orthogonal assays (reporter, Co-IP, pulldown, siRNA) in single study; no structural validation or in vivo rescue","pmids":["16990252"],"is_preprint":false},{"year":2011,"finding":"FLII (Flightless I) is a novel mediator of skin blistering in epidermolysis bullosa (EB). Overexpression of Flii in mice exacerbated blistering severity in an autoimmune collagen VII (ColVII) model of EB acquisita, while reduced Flii expression decreased blister severity, elevated integrin expression, and improved ColVII production. Flii-deficient fibroblasts showed reduced ability to contract collagen gels in vitro, and TGF-β1 restored collagen contraction in Flii-deficient cells, indicating an interplay between Flii and the TGF-β1/Smad2/3 signaling pathway. Reduced Flii also decreased α-SMA and TGF-β1/Smad2/3 expression in blistered skin, suggesting Flii promotes fibrosis.","method":"Murine Flii allelic series (Flii overexpressing and Flii+/- mice), autoimmune ColVII EBA mouse model, ColVII hypomorphic genetic mouse model, collagen gel contraction assays, immunofluorescence, Western blot","journal":"The Journal of pathology","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal in vivo genetic models with specific mechanistic readouts (ColVII production, integrin expression, TGF-β/Smad pathway), replicated across two mouse models","pmids":["21984127"],"is_preprint":false}],"current_model":"FLII (Flightless I) is an actin-remodeling protein that acts as a transcriptional coactivator/corepressor (suppressing Wnt/beta-catenin signaling by antagonizing FLAP1-p300-beta-catenin complexes and activating nuclear receptor targets) and regulates skin integrity by modulating TGF-β1/Smad signaling, collagen VII production, and integrin expression, with its overexpression worsening and its deficiency ameliorating skin blistering in epidermolysis bullosa models."},"narrative":{"teleology":[{"year":2006,"claim":"Establishing that FLII operates as a dual transcriptional regulator — coactivating nuclear receptor targets while suppressing Wnt/β-catenin/LEF1/TCF-dependent transcription through disruption of the FLAP1–p300–β-catenin complex — answered how a single gelsolin-family protein could modulate both nuclear receptor and Wnt signaling outputs.","evidence":"Transient transfection reporter assays, co-immunoprecipitation, GST pull-down, and siRNA knockdown of FLAP1 in mammalian cell lines","pmids":["16990252"],"confidence":"Medium","gaps":["No structural or in vivo validation of the FLII–FLAP1–p300–β-catenin disruption mechanism","Endogenous chromatin context and genome-wide target genes of FLII transcriptional regulation are undefined","Whether FLII actin-binding and transcriptional activities are coupled or independent remains unresolved"]},{"year":2011,"claim":"Demonstrating that FLII dosage directly controls skin blistering severity in epidermolysis bullosa models — with overexpression worsening and haploinsufficiency ameliorating disease through modulation of collagen VII, integrin expression, and TGF-β1/Smad2/3 signaling — established FLII as a pathogenic mediator in EB and linked its function to fibrotic remodeling in vivo.","evidence":"Flii allelic series (overexpression and heterozygous knockout) in autoimmune collagen VII EBA and ColVII hypomorphic mouse models, collagen gel contraction assays, immunofluorescence, and Western blot","pmids":["21984127"],"confidence":"High","gaps":["Direct molecular mechanism by which FLII regulates TGF-β1/Smad2/3 signaling is not delineated","Whether FLII transcriptional co-regulation (Wnt/nuclear receptor) contributes to the blistering phenotype is untested","Therapeutic applicability of FLII reduction in human epidermolysis bullosa has not been demonstrated"]},{"year":null,"claim":"The relationship between FLII's actin-remodeling activity, its transcriptional co-regulatory roles, and its in vivo control of skin integrity remains mechanistically unintegrated — it is unknown whether these represent a single pathway or separable functions.","evidence":"","pmids":[],"confidence":"Low","gaps":["No domain-specific mutations separating actin-binding from transcriptional functions have been tested in vivo","Genome-wide transcriptional targets of FLII in skin and other tissues are uncharacterized","Structural basis for FLII interaction with FLAP1, p300, and β-catenin is unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0]},{"term_id":"GO:0008092","term_label":"cytoskeletal protein binding","supporting_discovery_ids":[1]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0]}],"pathway":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,1]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[1]}],"complexes":[],"partners":["FLAP1","CTNNB1","EP300","GRIP1"],"other_free_text":[]},"mechanistic_narrative":"FLII (Protein flightless-1 homolog) is an actin-remodeling protein that functions as a transcriptional coactivator for nuclear receptor targets and as a repressor of Wnt/β-catenin signaling by disrupting the FLAP1–p300–β-catenin complex [PMID:16990252]. FLII regulates skin integrity and blistering severity in epidermolysis bullosa: overexpression exacerbates blistering in murine collagen VII models, while reduced FLII expression improves collagen VII production, elevates integrin expression, and attenuates TGF-β1/Smad2/3-driven fibrosis [PMID:21984127]."},"prefetch_data":{"uniprot":{"accession":"Q13045","full_name":"Protein flightless-1 homolog","aliases":[],"length_aa":1269,"mass_kda":144.8,"function":"Is a regulator of actin polymerization, required for proper myofibril organization and regulation of the length of sarcomeric thin filaments (By similarity). It also plays a role in the assembly of cardiomyocyte cell adhesion complexes (By similarity). Regulates cytoskeletal rearrangements involved in cytokinesis and cell migration, by inhibiting Rac1-dependent paxillin phosphorylation (By similarity). May play a role as coactivator in transcriptional activation by hormone-activated nuclear receptors (NR) and acts in cooperation with NCOA2 and CARM1 (PubMed:14966289). Involved in estrogen hormone signaling","subcellular_location":"Nucleus; Cytoplasm, cytoskeleton; Cytoplasm, cytoskeleton, microtubule organizing center, centrosome; Cell projection, podosome; Cell junction, focal adhesion","url":"https://www.uniprot.org/uniprotkb/Q13045/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/FLII","classification":"Not Classified","n_dependent_lines":434,"n_total_lines":1208,"dependency_fraction":0.35927152317880795},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"ACTB","stoichiometry":0.2},{"gene":"ACTG1","stoichiometry":0.2},{"gene":"CALD1","stoichiometry":0.2},{"gene":"CAPZB","stoichiometry":0.2},{"gene":"FKBP5","stoichiometry":0.2},{"gene":"MYL12A","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/FLII","total_profiled":1310},"omim":[{"mim_id":"620635","title":"CARDIOMYOPATHY, DILATED, 2J; CMD2J","url":"https://www.omim.org/entry/620635"},{"mim_id":"614043","title":"LEUCINE-RICH REPEAT IN FLII-INTERACTING PROTEIN 2; LRRFIP2","url":"https://www.omim.org/entry/614043"},{"mim_id":"611377","title":"BRACHYDACTYLY, TYPE B2; BDB2","url":"https://www.omim.org/entry/611377"},{"mim_id":"603256","title":"LEUCINE-RICH REPEAT IN FLII-INTERACTING PROTEIN 1; LRRFIP1","url":"https://www.omim.org/entry/603256"},{"mim_id":"601052","title":"PEPTIDYL-PROLYL CIS/TRANS ISOMERASE, NIMA-INTERACTING, 1; PIN1","url":"https://www.omim.org/entry/601052"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoplasm","reliability":"Approved"},{"location":"Centriolar satellite","reliability":"Approved"},{"location":"Cytosol","reliability":"Approved"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"skeletal muscle","ntpm":239.7}],"url":"https://www.proteinatlas.org/search/FLII"},"hgnc":{"alias_symbol":["FLI","FLIL","Fli1","MGC39265"],"prev_symbol":[]},"alphafold":{"accession":"Q13045","domains":[{"cath_id":"3.80.10.10","chopping":"260-382","consensus_level":"medium","plddt":90.3172,"start":260,"end":382},{"cath_id":"3.40.20.10","chopping":"494-602","consensus_level":"medium","plddt":89.4921,"start":494,"end":602},{"cath_id":"3.40.20.10","chopping":"621-707","consensus_level":"medium","plddt":88.3016,"start":621,"end":707},{"cath_id":"3.40.20.10","chopping":"725-746_768-835","consensus_level":"high","plddt":85.3087,"start":725,"end":835},{"cath_id":"3.40.20.10","chopping":"1160-1257","consensus_level":"high","plddt":84.1598,"start":1160,"end":1257}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q13045","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q13045-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q13045-F1-predicted_aligned_error_v6.png","plddt_mean":80.94},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=FLII","jax_strain_url":"https://www.jax.org/strain/search?query=FLII"},"sequence":{"accession":"Q13045","fasta_url":"https://rest.uniprot.org/uniprotkb/Q13045.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q13045/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q13045"}},"corpus_meta":[{"pmid":"16234507","id":"PMC_16234507","title":"Immunohistochemical expression of endothelial markers CD31, CD34, von Willebrand factor, and Fli-1 in normal human tissues.","date":"2005","source":"The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society","url":"https://pubmed.ncbi.nlm.nih.gov/16234507","citation_count":661,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10981960","id":"PMC_10981960","title":"Fli-1 is required for murine vascular and megakaryocytic development and is hemizygously deleted in patients with thrombocytopenia.","date":"2000","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/10981960","citation_count":296,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29513652","id":"PMC_29513652","title":"EWS-FLI1 increases transcription to cause R-loops and block BRCA1 repair in Ewing sarcoma.","date":"2018","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/29513652","citation_count":254,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18216858","id":"PMC_18216858","title":"Distinct roles of the FliI ATPase and proton motive force in bacterial flagellar protein export.","date":"2008","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/18216858","citation_count":245,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1646201","id":"PMC_1646201","title":"Salmonella typhimurium mutants defective in flagellar filament regrowth and sequence similarity of FliI to F0F1, vacuolar, and archaebacterial ATPase subunits.","date":"1991","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/1646201","citation_count":184,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17962413","id":"PMC_17962413","title":"Gata2, Fli1, and Scl form a recursively wired gene-regulatory circuit during early hematopoietic development.","date":"2007","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/17962413","citation_count":183,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7503813","id":"PMC_7503813","title":"EWS/Fli-1 chimeric protein is a transcriptional activator.","date":"1993","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/7503813","citation_count":159,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29358035","id":"PMC_29358035","title":"EWS/FLI Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing Sarcoma.","date":"2018","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/29358035","citation_count":134,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17202259","id":"PMC_17202259","title":"Structural similarity between the flagellar type III ATPase FliI and F1-ATPase subunits.","date":"2007","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/17202259","citation_count":124,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20547696","id":"PMC_20547696","title":"Oncogenic partnerships: EWS-FLI1 protein interactions initiate key pathways of Ewing's sarcoma.","date":"2010","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/20547696","citation_count":120,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12556498","id":"PMC_12556498","title":"Functional cross-antagonism between transcription factors FLI-1 and EKLF.","date":"2003","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/12556498","citation_count":114,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24909161","id":"PMC_24909161","title":"The ets transcription factor Fli-1 in development, cancer and disease.","date":"2014","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/24909161","citation_count":113,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16740692","id":"PMC_16740692","title":"Oncoprotein EWS-FLI1 activity is enhanced by RNA helicase A.","date":"2006","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/16740692","citation_count":112,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11175364","id":"PMC_11175364","title":"The role of Fli-1 in normal cell function and malignant transformation.","date":"2000","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/11175364","citation_count":105,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12787361","id":"PMC_12787361","title":"Oligomerization and activation of the FliI ATPase central to bacterial flagellum assembly.","date":"2003","source":"Molecular microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/12787361","citation_count":94,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34329586","id":"PMC_34329586","title":"TRIM8 modulates the EWS/FLI oncoprotein to promote survival in Ewing sarcoma.","date":"2021","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/34329586","citation_count":90,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10102630","id":"PMC_10102630","title":"FLI-1 inhibits differentiation and induces proliferation of primary erythroblasts.","date":"1999","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/10102630","citation_count":90,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7932752","id":"PMC_7932752","title":"Caulobacter flagellar function, but not assembly, requires FliL, a non-polarly localized membrane protein present in all cell types.","date":"1994","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/7932752","citation_count":81,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19920188","id":"PMC_19920188","title":"EWS/FLI and its downstream target NR0B1 interact directly to modulate transcription and oncogenesis in Ewing's sarcoma.","date":"2009","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/19920188","citation_count":75,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16556028","id":"PMC_16556028","title":"Ewing's sarcoma oncoprotein EWS-FLI1: the perfect target without a therapeutic agent.","date":"2005","source":"Future oncology (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/16556028","citation_count":72,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18284590","id":"PMC_18284590","title":"FliL is essential for swarming: motor rotation in absence of FliL fractures the flagellar rod in swarmer cells of Salmonella enterica.","date":"2008","source":"Molecular microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/18284590","citation_count":71,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21441522","id":"PMC_21441522","title":"A novel gene inactivation system reveals altered periplasmic flagellar orientation in a Borrelia burgdorferi fliL mutant.","date":"2011","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/21441522","citation_count":68,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28232470","id":"PMC_28232470","title":"Epithelial Fli1 deficiency drives systemic autoimmunity and fibrosis: Possible roles in scleroderma.","date":"2017","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28232470","citation_count":67,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16113269","id":"PMC_16113269","title":"Role of FliF and FliI of Listeria monocytogenes in flagellar assembly and pathogenicity.","date":"2005","source":"Infection and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/16113269","citation_count":65,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25284201","id":"PMC_25284201","title":"Assembly dynamics and the roles of FliI ATPase of the bacterial flagellar export apparatus.","date":"2014","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/25284201","citation_count":64,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18641300","id":"PMC_18641300","title":"The transcription factor Fli-1 modulates marginal zone and follicular B cell development in mice.","date":"2008","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/18641300","citation_count":63,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16990252","id":"PMC_16990252","title":"Interplay of Fli-I and FLAP1 for regulation of beta-catenin dependent transcription.","date":"2006","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/16990252","citation_count":62,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30500808","id":"PMC_30500808","title":"Downregulation of ERG and FLI1 expression in endothelial cells triggers endothelial-to-mesenchymal transition.","date":"2018","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/30500808","citation_count":61,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2515410","id":"PMC_2515410","title":"Trigeminal nerve section induces Fos-like immunoreactivity (FLI) in brainstem and decreases FLI in sensory cortex.","date":"1989","source":"Brain research. Molecular brain research","url":"https://pubmed.ncbi.nlm.nih.gov/2515410","citation_count":61,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34060252","id":"PMC_34060252","title":"SPOP and OTUD7A Control EWS-FLI1 Protein Stability to Govern Ewing Sarcoma Growth.","date":"2021","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/34060252","citation_count":59,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26848860","id":"PMC_26848860","title":"Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26848860","citation_count":59,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15491164","id":"PMC_15491164","title":"Recombinant EWS-FLI1 oncoprotein activates transcription.","date":"2004","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15491164","citation_count":51,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15994290","id":"PMC_15994290","title":"Fli1, Elf1, and Ets1 regulate the proximal promoter of the LMO2 gene in endothelial cells.","date":"2005","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/15994290","citation_count":51,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25714720","id":"PMC_25714720","title":"A new player at the flagellar motor: FliL controls both motor output and bias.","date":"2015","source":"mBio","url":"https://pubmed.ncbi.nlm.nih.gov/25714720","citation_count":50,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26258070","id":"PMC_26258070","title":"EWS/FLI1 Target Genes and Therapeutic Opportunities in Ewing Sarcoma.","date":"2015","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/26258070","citation_count":49,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20156317","id":"PMC_20156317","title":"Downstream EWS/FLI1 - upstream Ewing's sarcoma.","date":"2010","source":"Genome medicine","url":"https://pubmed.ncbi.nlm.nih.gov/20156317","citation_count":49,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23926301","id":"PMC_23926301","title":"Deregulation of ETS1 and FLI1 contributes to the pathogenesis of diffuse large B-cell lymphoma.","date":"2013","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/23926301","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22111876","id":"PMC_22111876","title":"Interaction between FliI ATPase and a flagellar chaperone FliT during bacterial flagellar protein export.","date":"2011","source":"Molecular microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/22111876","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30723142","id":"PMC_30723142","title":"Trabectedin Inhibits EWS-FLI1 and Evicts SWI/SNF from Chromatin in a Schedule-dependent Manner.","date":"2019","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/30723142","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20889747","id":"PMC_20889747","title":"The flagellar protein FliL is essential for swimming in Rhodobacter sphaeroides.","date":"2010","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/20889747","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37875710","id":"PMC_37875710","title":"Fatty liver index (FLI): more than a marker of hepatic steatosis.","date":"2023","source":"Journal of physiology and biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/37875710","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22829238","id":"PMC_22829238","title":"Drug-mediated inhibition of Fli-1 for the treatment of leukemia.","date":"2012","source":"Blood cancer journal","url":"https://pubmed.ncbi.nlm.nih.gov/22829238","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19074838","id":"PMC_19074838","title":"EWS-Fli1 up-regulates expression of the Aurora A and Aurora B kinases.","date":"2008","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/19074838","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20103643","id":"PMC_20103643","title":"EWS/FLI1 oncogene activates caspase 3 transcription and triggers apoptosis in vivo.","date":"2010","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/20103643","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11431376","id":"PMC_11431376","title":"The COOH-terminal domain of FLI-1 is necessary for full tumorigenesis and transcriptional modulation by EWS/FLI-1.","date":"2001","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/11431376","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30890608","id":"PMC_30890608","title":"Structure of Vibrio FliL, a New Stomatin-like Protein That Assists the Bacterial Flagellar Motor Function.","date":"2019","source":"mBio","url":"https://pubmed.ncbi.nlm.nih.gov/30890608","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36658219","id":"PMC_36658219","title":"ETV6 dependency in Ewing sarcoma by antagonism of EWS-FLI1-mediated enhancer activation.","date":"2023","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/36658219","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9286988","id":"PMC_9286988","title":"Identification of the fliI and fliJ components of the Caulobacter flagellar type III protein secretion system.","date":"1997","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/9286988","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20665663","id":"PMC_20665663","title":"The Ewing's sarcoma fusion protein, EWS-FLI, binds Runx2 and blocks osteoblast differentiation.","date":"2010","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20665663","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27166877","id":"PMC_27166877","title":"Preclinical Justification of pbi-shRNA EWS/FLI1 Lipoplex (LPX) Treatment for Ewing's Sarcoma.","date":"2016","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/27166877","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24727028","id":"PMC_24727028","title":"Fli1 acts downstream of Etv2 to govern cell survival and vascular homeostasis via positive autoregulation.","date":"2014","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/24727028","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38816360","id":"PMC_38816360","title":"FLI1 promotes IFN-γ-induced kynurenine production to impair anti-tumor immunity.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/38816360","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25098295","id":"PMC_25098295","title":"The Fli-1 transcription factor regulates the expression of CCL5/RANTES.","date":"2014","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/25098295","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12432241","id":"PMC_12432241","title":"EWS-FLI1 and Ewing's sarcoma: recent molecular data and new insights.","date":"2002","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/12432241","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30741932","id":"PMC_30741932","title":"Identification of diterpenoid compounds that interfere with Fli-1 DNA binding to suppress leukemogenesis.","date":"2019","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/30741932","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35046042","id":"PMC_35046042","title":"The flagellar motor protein FliL forms a scaffold of circumferentially positioned rings required for stator activation.","date":"2022","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/35046042","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35412146","id":"PMC_35412146","title":"Current insights into the role of Fli-1 in hematopoiesis and malignant transformation.","date":"2022","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/35412146","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19665005","id":"PMC_19665005","title":"ATP-induced FliI hexamerization facilitates bacterial flagellar protein export.","date":"2009","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/19665005","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28248553","id":"PMC_28248553","title":"Synergistic Role of Endothelial ERG and FLI1 in Mediating Pulmonary Vascular Homeostasis.","date":"2017","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/28248553","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8157599","id":"PMC_8157599","title":"Characterization of the fliL gene in the flagellar regulon of Escherichia coli and Salmonella typhimurium.","date":"1994","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/8157599","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21984127","id":"PMC_21984127","title":"Overexpression of the Flii gene increases dermal-epidermal blistering in an autoimmune ColVII mouse model of epidermolysis bullosa acquisita.","date":"2011","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/21984127","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28255014","id":"PMC_28255014","title":"Macrothrombocytopenia and dense granule deficiency associated with FLI1 variants: ultrastructural and pathogenic features.","date":"2017","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/28255014","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30700749","id":"PMC_30700749","title":"USP19 deubiquitinates EWS-FLI1 to regulate Ewing sarcoma growth.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/30700749","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33080033","id":"PMC_33080033","title":"EWS-FLI1 regulates and cooperates with core regulatory circuitry in Ewing sarcoma.","date":"2020","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/33080033","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15273724","id":"PMC_15273724","title":"Role of protein-protein interactions in the antiapoptotic function of EWS-Fli-1.","date":"2004","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/15273724","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28432223","id":"PMC_28432223","title":"FLI1 level during megakaryopoiesis affects thrombopoiesis and platelet biology.","date":"2017","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/28432223","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21084965","id":"PMC_21084965","title":"FLI-1 distinguishes Ewing sarcoma from small cell osteosarcoma and mesenchymal chondrosarcoma.","date":"2011","source":"Applied immunohistochemistry & molecular morphology : AIMM","url":"https://pubmed.ncbi.nlm.nih.gov/21084965","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26916245","id":"PMC_26916245","title":"FliH and FliI ensure efficient energy coupling of flagellar type III protein export in Salmonella.","date":"2016","source":"MicrobiologyOpen","url":"https://pubmed.ncbi.nlm.nih.gov/26916245","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9444955","id":"PMC_9444955","title":"Functional interference between retinoic acid or steroid hormone receptors and the oncoprotein Fli-1.","date":"1997","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/9444955","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23320737","id":"PMC_23320737","title":"The transcription factor Fli-1 regulates monocyte, macrophage and dendritic cell development in mice.","date":"2013","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23320737","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26961871","id":"PMC_26961871","title":"Englerin A Inhibits EWS-FLI1 DNA Binding in Ewing Sarcoma Cells.","date":"2016","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26961871","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34976713","id":"PMC_34976713","title":"One oncogene, several vulnerabilities: EWS/FLI targeted therapies for Ewing sarcoma.","date":"2021","source":"Journal of bone oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34976713","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25331431","id":"PMC_25331431","title":"Loss of FliL alters Proteus mirabilis surface sensing and temperature-dependent swarming.","date":"2014","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/25331431","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26055516","id":"PMC_26055516","title":"Epigenetic suppression of Fli1, a potential predisposing factor in the pathogenesis of systemic sclerosis.","date":"2015","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/26055516","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27587584","id":"PMC_27587584","title":"Structures of mithramycin analogues bound to DNA and implications for targeting transcription factor FLI1.","date":"2016","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/27587584","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35653119","id":"PMC_35653119","title":"EWS::FLI1 and HOXD13 Control Tumor Cell Plasticity in Ewing Sarcoma.","date":"2022","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/35653119","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18271016","id":"PMC_18271016","title":"EWS/FLI1 suppresses retinoblastoma protein function and senescence in Ewing's sarcoma cells.","date":"2008","source":"Journal of orthopaedic research : official publication of the Orthopaedic Research Society","url":"https://pubmed.ncbi.nlm.nih.gov/18271016","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33097530","id":"PMC_33097530","title":"RING1B recruits EWSR1-FLI1 and cooperates in the remodeling of chromatin necessary for Ewing sarcoma tumorigenesis.","date":"2020","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/33097530","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23222728","id":"PMC_23222728","title":"Activity of Proteus mirabilis FliL is viscosity dependent and requires extragenic DNA.","date":"2012","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/23222728","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20110178","id":"PMC_20110178","title":"Loss of GATA1 and gain of FLI1 expression during thrombocyte maturation.","date":"2010","source":"Blood cells, molecules & diseases","url":"https://pubmed.ncbi.nlm.nih.gov/20110178","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34359682","id":"PMC_34359682","title":"Therapeutic Potential of EWSR1-FLI1 Inactivation by CRISPR/Cas9 in Ewing Sarcoma.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/34359682","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34035145","id":"PMC_34035145","title":"Fusion protein EWS-FLI1 is incorporated into a protein granule in cells.","date":"2021","source":"RNA (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/34035145","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35288713","id":"PMC_35288713","title":"The transcription factor Fli1 restricts the formation of memory precursor NK cells during viral infection.","date":"2022","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35288713","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35038582","id":"PMC_35038582","title":"Suppression of Fli-1 protects against pericyte loss and cognitive deficits in Alzheimer's disease.","date":"2022","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/35038582","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36074578","id":"PMC_36074578","title":"The druggable transcription factor Fli-1 regulates T cell immunity and tolerance in graft-versus-host disease.","date":"2022","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/36074578","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9388029","id":"PMC_9388029","title":"Production and characterization of mouse monoclonal antibodies to wild-type and oncogenic FLI-1 proteins.","date":"1997","source":"Hybridoma","url":"https://pubmed.ncbi.nlm.nih.gov/9388029","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33234418","id":"PMC_33234418","title":"Emerging role of Fli1 in autoimmune diseases.","date":"2020","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/33234418","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32508810","id":"PMC_32508810","title":"Fli1 Downregulation in Scleroderma Myeloid Cells Has Profibrotic and Proinflammatory Effects.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32508810","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36357572","id":"PMC_36357572","title":"Therapeutic targeting the oncogenic driver EWSR1::FLI1 in Ewing sarcoma through inhibition of the FACT complex.","date":"2022","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/36357572","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27431361","id":"PMC_27431361","title":"Acetylation impacts Fli-1-driven regulation of granulocyte colony stimulating factor.","date":"2016","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/27431361","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24415532","id":"PMC_24415532","title":"EWS-FLI-1 regulates the neuronal repressor gene REST, which controls Ewing sarcoma growth and vascular morphology.","date":"2014","source":"Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/24415532","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16941013","id":"PMC_16941013","title":"Solid pseudopapillary neoplasms of the pancreas are associated with FLI-1 expression, but not with EWS/FLI-1 translocation.","date":"2006","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/16941013","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22973553","id":"PMC_22973553","title":"Acetylation Increases EWS-FLI1 DNA Binding and Transcriptional Activity.","date":"2012","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/22973553","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31846072","id":"PMC_31846072","title":"The transcription factor FLI1 promotes cancer progression by affecting cell cycle regulation.","date":"2020","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/31846072","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37894854","id":"PMC_37894854","title":"EWS/FLI1 Characterization, Activation, Repression, Target Genes and Therapeutic Opportunities in Ewing Sarcoma.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37894854","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26336820","id":"PMC_26336820","title":"PI3K/AKT signaling modulates transcriptional expression of EWS/FLI1 through specificity protein 1.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26336820","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26618620","id":"PMC_26618620","title":"Structural Basis for Dimerization and DNA Binding of Transcription Factor FLI1.","date":"2015","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26618620","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32164354","id":"PMC_32164354","title":"High Specificity of BCL11B and GLG1 for EWSR1-FLI1 and EWSR1-ERG Positive Ewing Sarcoma.","date":"2020","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/32164354","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35500152","id":"PMC_35500152","title":"Super enhancer-LncRNA SENCR promoted cisplatin resistance and growth of NSCLC through upregulating FLI1.","date":"2022","source":"Journal of clinical laboratory analysis","url":"https://pubmed.ncbi.nlm.nih.gov/35500152","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10350613","id":"PMC_10350613","title":"Interaction of FliI, a component of the flagellar export apparatus, with flagellin and hook protein.","date":"1999","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/10350613","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17081983","id":"PMC_17081983","title":"Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.","date":"2006","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/17081983","citation_count":2861,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16169070","id":"PMC_16169070","title":"A human protein-protein interaction network: a resource for annotating the proteome.","date":"2005","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/16169070","citation_count":1704,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16964243","id":"PMC_16964243","title":"A probability-based approach for high-throughput protein phosphorylation analysis and site localization.","date":"2006","source":"Nature biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/16964243","citation_count":1336,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18187620","id":"PMC_18187620","title":"Identification of host proteins required for HIV infection through a functional genomic screen.","date":"2008","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/18187620","citation_count":1165,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15302935","id":"PMC_15302935","title":"Large-scale characterization of HeLa cell nuclear phosphoproteins.","date":"2004","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/15302935","citation_count":1159,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26186194","id":"PMC_26186194","title":"The BioPlex Network: A Systematic Exploration of the Human Interactome.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26186194","citation_count":1118,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28514442","id":"PMC_28514442","title":"Architecture of the human interactome defines protein communities and disease networks.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28514442","citation_count":1085,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26496610","id":"PMC_26496610","title":"A human interactome in three quantitative dimensions organized by stoichiometries and abundances.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26496610","citation_count":1015,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"29507755","id":"PMC_29507755","title":"VIRMA mediates preferential m6A mRNA methylation in 3'UTR and near stop codon and associates with alternative polyadenylation.","date":"2018","source":"Cell discovery","url":"https://pubmed.ncbi.nlm.nih.gov/29507755","citation_count":829,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22939629","id":"PMC_22939629","title":"A census of human soluble protein complexes.","date":"2012","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/22939629","citation_count":689,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"29395067","id":"PMC_29395067","title":"High-Density Proximity Mapping Reveals the Subcellular Organization of mRNA-Associated Granules and Bodies.","date":"2018","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/29395067","citation_count":580,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33060197","id":"PMC_33060197","title":"Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms.","date":"2020","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/33060197","citation_count":564,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12665801","id":"PMC_12665801","title":"Exploring proteomes and analyzing protein processing by mass spectrometric identification of sorted N-terminal peptides.","date":"2003","source":"Nature biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/12665801","citation_count":485,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26638075","id":"PMC_26638075","title":"A Dynamic Protein Interaction Landscape of the Human Centrosome-Cilium Interface.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26638075","citation_count":433,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"35271311","id":"PMC_35271311","title":"OpenCell: Endogenous tagging for the cartography of human cellular organization.","date":"2022","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/35271311","citation_count":432,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26344197","id":"PMC_26344197","title":"Panorama of ancient metazoan macromolecular complexes.","date":"2015","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/26344197","citation_count":407,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8889548","id":"PMC_8889548","title":"Normalization and subtraction: two approaches to facilitate gene discovery.","date":"1996","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/8889548","citation_count":401,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26414014","id":"PMC_26414014","title":"Proteome-wide profiling of protein assemblies by cross-linking mass spectrometry.","date":"2015","source":"Nature methods","url":"https://pubmed.ncbi.nlm.nih.gov/26414014","citation_count":370,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"34079125","id":"PMC_34079125","title":"A proximity-dependent biotinylation map of a human cell.","date":"2021","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/34079125","citation_count":339,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22863883","id":"PMC_22863883","title":"A high-throughput approach for measuring temporal changes in the interactome.","date":"2012","source":"Nature methods","url":"https://pubmed.ncbi.nlm.nih.gov/22863883","citation_count":273,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21654808","id":"PMC_21654808","title":"A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers.","date":"2011","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/21654808","citation_count":269,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"25281560","id":"PMC_25281560","title":"Proximity biotinylation and affinity purification are complementary approaches for the interactome mapping of chromatin-associated protein complexes.","date":"2014","source":"Journal of proteomics","url":"https://pubmed.ncbi.nlm.nih.gov/25281560","citation_count":215,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26618866","id":"PMC_26618866","title":"∆F508 CFTR interactome remodelling promotes rescue of cystic fibrosis.","date":"2015","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/26618866","citation_count":209,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19913121","id":"PMC_19913121","title":"Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip.","date":"2009","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19913121","citation_count":164,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32877691","id":"PMC_32877691","title":"A High-Density Human Mitochondrial Proximity Interaction Network.","date":"2020","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/32877691","citation_count":148,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"30554943","id":"PMC_30554943","title":"Interactome Rewiring Following Pharmacological Targeting of BET Bromodomains.","date":"2018","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/30554943","citation_count":136,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":47514,"output_tokens":6038,"usd":0.116556},"stage2":{"model":"claude-opus-4-6","input_tokens":9677,"output_tokens":4794,"usd":0.252352},"total_usd":0.548447,"stage1_batch_id":"msgbatch_0118RScg3WGaGkaZRtWZbtce","stage2_batch_id":"msgbatch_01Cpfzvtbj42aqp5oYZ5Te2s","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":59582,"output_tokens":1683,"usd":0.101996},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":4344,"output_tokens":1199,"usd":0.077543}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2000,\n      \"finding\": \"Fli-1 null mutation in mice causes embryonic lethality at day 11.5 with loss of vascular integrity and specific downregulation of Tek/Tie-2 (angiopoietin-1 receptor), establishing Fli-1 as a transcriptional regulator required for vascular integrity and megakaryocytic development\",\n      \"method\": \"Targeted null mutation in mice (knockout), in vivo phenotypic analysis\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with defined cellular and molecular phenotype, replicated in developmental context\",\n      \"pmids\": [\"10981960\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"EWS/Fli-1 chimeric protein functions as a transcriptional activator; deletion analysis showed the EWS domain acts as a modulatory/regulatory domain for the carboxy-terminal transcriptional activation domain of Fli-1, and replacement of the Fli-1 N-terminal activation domain with EWS NTD activates the C-terminal activation domain\",\n      \"method\": \"Transient transfection reporter assays, deletion mutagenesis\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple deletion mutant constructs with functional transcription assays, foundational paper >150 citations\",\n      \"pmids\": [\"7503813\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"FLI-1 represses EKLF-dependent transcription through the repression activity of its ETS DNA-binding domain, and is recruited indirectly to erythroid promoters via protein-protein interaction with EKLF; conversely, EKLF represses FLI-1-dependent megakaryocytic (GPIX) promoter, establishing functional cross-antagonism between FLI-1 and EKLF in erythroid vs. megakaryocytic fate decisions\",\n      \"method\": \"Co-immunoprecipitation, GST pulldown, transient transfection reporter assays, Gal4 fusion domain analysis\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal functional antagonism established with multiple orthogonal methods including protein interaction and promoter assays\",\n      \"pmids\": [\"12556498\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Flightless-I (Fli-I) serves as a coactivator for nuclear receptor-mediated transcription and inhibits beta-catenin/LEF1/TCF-dependent transcription; FLAP1 (Fli-I leucine-rich repeat associated protein 1) directly interacts with beta-catenin, GRIP1, and p300 and activates Wnt/beta-catenin signaling, while Fli-I disrupts the synergy of FLAP1 with p300 and beta-catenin\",\n      \"method\": \"Co-immunoprecipitation, GST pulldown, transient transfection reporter assays, siRNA knockdown\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (pulldown, co-IP, reporter assays, knockdown) in a single study\",\n      \"pmids\": [\"16990252\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Gata2, Fli1, and Scl form a recursively wired gene-regulatory circuit during early hematopoiesis; each transcription factor binds the enhancers of the other two (fully connected triad), established by chromatin immunoprecipitation at Fli1+12, Gata2-3, and Scl+19 enhancers in embryonic day-11.5 dorsal aorta and fetal liver\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP), transgenic enhancer analysis, in vivo binding assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP-based binding validated in multiple tissues with enhancer transgenic analysis\",\n      \"pmids\": [\"17962413\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Fli-1 and retinoic acid receptor alpha (RARα) reciprocally repress each other's transcriptional activation; the DNA-binding domain of RARα and N-terminal region of Fli-1 are required for repression, and the interaction appears to be mediated by a bridging factor in nuclear extracts rather than direct DNA binding competition\",\n      \"method\": \"Transient transfection reporter assays, gel retardation (EMSA), deletion mutagenesis\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple methods (reporter assays, EMSA, mutagenesis) in single lab\",\n      \"pmids\": [\"9444955\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"FLI-1 overexpression in primary erythroblasts inhibits terminal differentiation and apoptosis, induces proliferation, upregulates bcl2 expression, and prevents downregulation of cyclin D2 and D3, independently of cooperation with activated EpoR\",\n      \"method\": \"Retroviral overexpression in primary avian erythroblasts, proliferation/differentiation assays, Western blot for cell cycle regulators\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — gain-of-function with defined molecular readouts and comparison to PU.1, single lab\",\n      \"pmids\": [\"10102630\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"EWS-Fli-1 and Fli-1 interact with CBP through their amino-terminal regions, inhibiting CBP-dependent transcriptional activity of RXR; this antiapoptotic activity is independent of EWS-Fli-1 DNA-binding activity\",\n      \"method\": \"Co-immunoprecipitation, transient transfection reporter assays, dominant-negative CBP expression in Ewing sarcoma cells\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — co-IP and functional reporter assays, single lab\",\n      \"pmids\": [\"15273724\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Fli1, Elf1, and Ets1 bind to conserved Ets sites in the proximal LMO2 promoter and regulate its activity in endothelial cells in vivo; Fli1 binding to LMO2 promoter was confirmed by ChIP in hematopoietic progenitor and endothelial cell lines\",\n      \"method\": \"ChIP, transient and stable transfection, transgenic mouse analysis\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP plus transgenic validation, single lab\",\n      \"pmids\": [\"15994290\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Fli-1 modulates marginal zone and follicular B cell development; truncation of the C-terminal transcriptional activation domain (CTA) of Fli-1 reduces follicular B cells and alters expression of B cell developmental genes (Igα, Pax-5, E2A, Egr-1, Id1, Id2), with bone marrow reconstitution confirming lymphocyte-intrinsic effects\",\n      \"method\": \"Knock-in mouse expressing truncated Fli-1(ΔCTA), bone marrow reconstitution, flow cytometry, gene expression analysis\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic loss-of-function with defined cellular phenotype and molecular targets, bone marrow reconstitution confirms cell-intrinsic mechanism\",\n      \"pmids\": [\"18641300\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Fli-1 C-terminal transcriptional activation domain negatively modulates mononuclear phagocyte development; Fli-1 protein binds directly to the promoter region of Flt3L gene, and Fli-1(ΔCTA) mice show increased dendritic cell and macrophage populations with elevated Flt3L in multipotent progenitors\",\n      \"method\": \"Knock-in mouse, bone marrow reconstitution, ChIP (Fli-1 binding to Flt3L promoter), flow cytometry\",\n      \"journal\": \"Immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic model with ChIP-confirmed direct target, single lab\",\n      \"pmids\": [\"23320737\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Fli1 directly binds conserved Ets sites within the promoter and enhancer regions of its own gene (positive autoregulation) and Tie2, sustaining endothelial gene expression after Etv2 ceases to be expressed at midgestation; Etv2 initially activates Fli1 by binding Ets sites in the Fli1 promoter\",\n      \"method\": \"ChIP, loss- and gain-of-function in vivo, promoter binding assays\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP-validated binding plus genetic loss/gain-of-function, single lab\",\n      \"pmids\": [\"24727028\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Fli-1 binds to Ets binding sites in the distal CCL5 promoter and drives CCL5 transcription in a dose-dependent manner; mutation of the Fli-1 DNA-binding domain significantly reduces CCL5 promoter transactivation; Ets1 acts as a dominant-negative for Fli-1 at shared binding sites in the CCL5 promoter\",\n      \"method\": \"ChIP, transient transfection reporter assays, siRNA knockdown, DNA binding domain mutagenesis\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP plus reporter assay with mutagenesis, single lab\",\n      \"pmids\": [\"25098295\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Crystal structures of the FLI1 DNA-binding domain (DBD/ETS domain) alone and in complex with cognate GGAA-containing DNA reveal a previously unrecognized homodimerization via a helix-swapped interface dominated by hydrophobic interactions between Phe362 residues; F362A mutation disrupts dimerization without perturbing structure or DNA binding\",\n      \"method\": \"X-ray crystallography, analytical ultracentrifugation, site-directed mutagenesis\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure with mutagenesis validation of dimerization interface\",\n      \"pmids\": [\"26618620\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Acetylation of the FLI1 C-terminal DNA-binding domain (FLI1-CTD) by PCAF increases DNA binding activity of FLI1-CTD in vitro; PCAF overexpression or HDAC inhibitor treatment increases EWS-FLI1 transcriptional activity in cells\",\n      \"method\": \"In vitro acetylation assay, DNA binding assay (EMSA), transient transfection reporter assay\",\n      \"journal\": \"Frontiers in oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro enzymatic assay plus cell-based reporter, but full-length protein acetylation in ES cells remains unclear per authors\",\n      \"pmids\": [\"22973553\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Acetylation of Fli-1 at a known acetylation site by p300/CBP and PCAF significantly decreases Fli-1-specific activation of the G-CSF promoter; mutation of the acetylation site leads to increased G-CSF promoter activation, establishing acetylation as a negative regulatory PTM for Fli-1 transcriptional activity\",\n      \"method\": \"Transient transfection reporter assays, ChIP, site-directed mutagenesis of acetylation site, siRNA knockdown\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP plus mutagenesis and reporter assays, single lab\",\n      \"pmids\": [\"27431361\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Epithelial cell-specific Fli1 knockout mice spontaneously develop dermal and esophageal fibrosis and autoimmunity with thymic defects; Fli1 directly regulates Aire expression in epithelial cells (established by direct Fli1 binding to Aire promoter/regulatory regions)\",\n      \"method\": \"Keratin 14-Cre conditional Fli1 knockout mice, ChIP for Fli1 binding to Aire regulatory regions, gene expression analysis\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — conditional KO with ChIP-confirmed direct target, single lab\",\n      \"pmids\": [\"28232470\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"FLI1 deficiency in megakaryocytes impairs thrombopoiesis, platelet yield, half-life and functionality; FLI1 heterozygosity negatively regulates ETS1 expression during megakaryopoiesis; FLI1 overexpression improves megakaryocyte yield and platelet functionality in vivo\",\n      \"method\": \"iPSC-derived megakaryocytes from Paris-Trousseau syndrome patient and FLI1+/- targeted iPSCs, in vivo platelet infusion studies, gene expression analysis\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — human iPSC model with in vivo validation and molecular pathway identification, single lab\",\n      \"pmids\": [\"28432223\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Combined knockdown of ERG and FLI1 in endothelial cells induces endothelial-to-mesenchymal transition (EndMT) with dynamic epigenetic changes; ERG and FLI1 are critical transcriptional activators for EC-specific genes, and microRNA-126 (a target) partially blocks EndMT induction\",\n      \"method\": \"siRNA knockdown, genome-wide epigenomic/transcriptomic analyses, functional EndMT assays\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genome-wide analyses plus functional phenotype, single lab\",\n      \"pmids\": [\"30500808\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TRIM8 is an E3 ubiquitin ligase that ubiquitinates and degrades EWS/FLI1 protein; TRIM8 knockout increases EWS/FLI1 protein levels, and excess EWS/FLI1 is not tolerated (oncogene overdose), establishing TRIM8 as a selective dependency in Ewing sarcoma\",\n      \"method\": \"CRISPR-Cas9 screen, ubiquitination assays, Western blot, genetic knockdown/knockout with viability assays\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genome-wide CRISPR screen plus mechanistic ubiquitination assays with multiple orthogonal validations\",\n      \"pmids\": [\"34329586\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"SPOP (E3 ubiquitin ligase) and OTUD7A (deubiquitinase) control EWS-FLI1 protein stability; casein kinase 1-mediated phosphorylation of the VTSSS degron in the FLI1 domain enhances SPOP activity to degrade EWS-FLI1; OTUD7A deubiquitinates and stabilizes EWS-FLI1\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assays, phosphorylation assays, CRISPR/siRNA knockdown with protein stability measurements, xenograft mouse model\",\n      \"journal\": \"Advanced science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — biochemical ubiquitination/deubiquitination assays with phosphorylation mechanism and in vivo validation\",\n      \"pmids\": [\"34060252\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Fli1 is induced by STAT5 signaling in NK cells and increases levels of pro-apoptotic factor Bim in early effector NK cells following viral infection, limiting memory precursor NK cell formation; Fli1 acts as a cell-intrinsic checkpoint restricting MP NK cell development\",\n      \"method\": \"Single-cell RNA sequencing, genetic KO (Fli1-deficient mice), ex vivo STAT5 stimulation, flow cytometry, epigenetic profiling\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — scRNA-seq plus genetic KO with defined molecular pathway (STAT5→Fli1→Bim), single lab\",\n      \"pmids\": [\"35288713\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"FLI1 orchestrates expression of CBP and STAT1 to facilitate chromatin accessibility and transcriptional activation of IDO1 in response to IFN-γ, leading to augmented kynurenine production that promotes CD8+ T cell exhaustion and Treg differentiation; pharmacological FLI1 inhibition blocks this CBP/STAT1-IDO1-Kyn axis\",\n      \"method\": \"ChIP, gene expression analysis, siRNA/pharmacological inhibition, T cell functional assays, in vivo tumor models\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP plus functional T cell assays with pharmacological rescue, single lab\",\n      \"pmids\": [\"38816360\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"USP19 is a deubiquitinase that stabilizes EWS-FLI1 protein by binding to the N-terminal EWS region; USP19 depletion reduces EWS-FLI1 protein levels and impairs Ewing sarcoma growth in vitro and in vivo; stabilization is specific to the fusion protein and not to wild-type EWSR1 or FLI1\",\n      \"method\": \"siRNA screen, co-immunoprecipitation, ubiquitination/protein stability assays, shRNA stable knockdown, xenograft tumor model\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — co-IP plus stability assays and in vivo validation, single lab\",\n      \"pmids\": [\"30700749\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Anti-Fli-1 drug treatment inhibits Fli-1 DNA binding to target genes (SHIP-1 and gata-1), and there is a positive relationship between loss of Fli-1 DNA-binding activity and Fli-1 phosphorylation; Fli-1 inhibition of DNA binding triggers further Fli-1 downregulation through miR-145 (whose promoter is normally repressed by Fli-1), establishing a Fli-1-miR-145 autoregulatory loop\",\n      \"method\": \"EMSA (DNA-binding assays), ChIP, drug treatment with phosphorylation analysis, reporter assays, in vivo leukemia model\",\n      \"journal\": \"Blood cancer journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — EMSA plus ChIP and in vivo model, single lab\",\n      \"pmids\": [\"22829238\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Flii overexpression increases dermal-epidermal blistering severity in an autoimmune ColVII mouse model; decreased Flii reduces blister severity, elevates integrin expression, improves ColVII production, reduces α-SMA/TGF-β1/Smad2/3 expression, and Flii-deficient fibroblasts show reduced collagen gel contraction that is restored by TGF-β1, suggesting interplay between Flii and TGF-β1 signaling\",\n      \"method\": \"Transgenic Flii overexpression and Flii+/- mice, autoimmune EBA model, immunofluorescence, collagen gel contraction assay\",\n      \"journal\": \"The Journal of pathology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple Flii allele mouse models with in vitro mechanistic follow-up, single lab\",\n      \"pmids\": [\"21984127\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"FLI1 is an ETS-family transcription factor that activates or represses target gene promoters by binding GGAA/ETS motifs (with a structurally defined homodimerization interface in its DBD), engages in protein–protein interactions with partners including EKLF, GATA-1, CBP, STAT1, and RARα to modulate hematopoietic/endothelial fate decisions, is subject to post-translational regulation by acetylation (reducing activity), phosphorylation, and ubiquitin-mediated degradation (via SPOP/TRIM8 as E3 ligases and USP19/OTUD7A as deubiquitinases), forms a self-sustaining autoregulatory circuit with Gata2 and Scl during hematopoiesis, governs megakaryocyte/platelet biogenesis and endothelial homeostasis, and when fused to EWS drives oncogenic transcriptional reprogramming in Ewing sarcoma.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\nI need to carefully classify each paper. The gene in question is **FLII** (Flightless I), a human actin-remodeling protein with LRR and gelsolin domains. It is distinct from:\n- **FLI1** (Friend leukemia integration 1) — an ETS transcription factor\n- **FliI** — bacterial flagellar ATPase\n- **FLI** — Fos-like immunoreactivity\n\nAfter reviewing all papers:\n\n**KEEP** (about canonical human FLII protein):\n- Paper [27] (PMID 16990252): \"Interplay of Fli-I and FLAP1 for regulation of beta-catenin dependent transcription\" — explicitly about Flightless-I (Fli-I) as a coactivator, mentions gelsolin domain, developmental protein, coactivator for nuclear receptor-mediated transcription. This is about FLII.\n- Paper [61] (PMID 21984127): \"Overexpression of the Flii gene increases dermal-epidermal blistering...\" — explicitly about Flightless I (Flii), actin remodelling protein, wound repair. This is about FLII.\n\nAll other papers are about:\n- FLI1 (ETS transcription factor): papers 1, 2, 6, 7, 11, 12, 13, 14, 17, 23, 26, 28, 29 (FLI = Fos-like), 30, 31, 33, 37, 42, 51, 52, 53, 55, 57, 59, 62, 66, 69, 70, 74, 75, 80, 83, 84, 85, 86, 87, 88, 90, 92, 94, 97\n- EWS-FLI1 fusion: papers 3, 8, 10, 16, 19, 20, 30, 31, 32, 34 (FliL), 35, 36, 38 (FliT), 39, 43, 44, 45, 47, 49, 50, 54, 63, 64, 65, 71, 72, 76, 77, 78, 81, 82, 89, 91, 93, 95, 96, 98, 99\n- FliI/FliL bacterial flagellar proteins: papers 4, 5, 9, 15, 18, 21, 22, 24, 25, 34, 38, 40, 46, 48, 56, 58, 60, 68, 73, 79, 100\n- FLI (fatty liver index): paper 41\n- Unrelated proteomics/interactome: additional papers 1-30 (none specifically about FLII mechanism)\n- Paper [29] in retrieved: PMID 2515410 about Fos-like immunoreactivity — EXCLUDE\n\nThe additional curated papers are all large-scale proteomics/interactome studies with no specific FLII mechanistic findings extractable.\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2006,\n      \"finding\": \"Flightless-I (Fli-I/FLII) functions as a coactivator for nuclear receptor-mediated transcription and inhibits beta-catenin/LEF1/TCF-dependent transcription. Fli-I was found to disrupt the synergy between FLAP1 (Fli-I leucine rich repeat associated protein 1), p300, and beta-catenin, thereby suppressing Wnt target gene activation. FLAP1 directly interacted with beta-catenin, GRIP1, and p300 and enhanced their transcriptional activity, while Fli-I counteracted this. The opposing activities of Fli-I and FLAP1 were proposed as a regulatory mechanism for Wnt/beta-catenin signaling, with Fli-I mutations potentially causing developmental defects (e.g., Drosophila flightless phenotype) through dysregulation of this pathway.\",\n      \"method\": \"Transient transfection reporter assays, co-immunoprecipitation, GST pull-down, siRNA knockdown of endogenous FLAP1\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — multiple orthogonal assays (reporter, Co-IP, pulldown, siRNA) in single study; no structural validation or in vivo rescue\",\n      \"pmids\": [\"16990252\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"FLII (Flightless I) is a novel mediator of skin blistering in epidermolysis bullosa (EB). Overexpression of Flii in mice exacerbated blistering severity in an autoimmune collagen VII (ColVII) model of EB acquisita, while reduced Flii expression decreased blister severity, elevated integrin expression, and improved ColVII production. Flii-deficient fibroblasts showed reduced ability to contract collagen gels in vitro, and TGF-β1 restored collagen contraction in Flii-deficient cells, indicating an interplay between Flii and the TGF-β1/Smad2/3 signaling pathway. Reduced Flii also decreased α-SMA and TGF-β1/Smad2/3 expression in blistered skin, suggesting Flii promotes fibrosis.\",\n      \"method\": \"Murine Flii allelic series (Flii overexpressing and Flii+/- mice), autoimmune ColVII EBA mouse model, ColVII hypomorphic genetic mouse model, collagen gel contraction assays, immunofluorescence, Western blot\",\n      \"journal\": \"The Journal of pathology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal in vivo genetic models with specific mechanistic readouts (ColVII production, integrin expression, TGF-β/Smad pathway), replicated across two mouse models\",\n      \"pmids\": [\"21984127\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"FLII (Flightless I) is an actin-remodeling protein that acts as a transcriptional coactivator/corepressor (suppressing Wnt/beta-catenin signaling by antagonizing FLAP1-p300-beta-catenin complexes and activating nuclear receptor targets) and regulates skin integrity by modulating TGF-β1/Smad signaling, collagen VII production, and integrin expression, with its overexpression worsening and its deficiency ameliorating skin blistering in epidermolysis bullosa models.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"FLI1 is an ETS-family transcription factor that governs vascular integrity, megakaryopoiesis, and hematopoietic lineage specification by binding GGAA/ETS motifs in target gene promoters and enhancers. Its DNA-binding domain homodimerizes via a helix-swapped hydrophobic interface centered on Phe362, and FLI1 participates in a self-reinforcing transcriptional circuit with GATA2 and SCL during early hematopoiesis while cross-antagonizing EKLF to direct megakaryocytic versus erythroid fate [PMID:26618620, PMID:17962413, PMID:12556498]. FLI1 transcriptional output is modulated by acetylation (p300/CBP and PCAF reduce activity at hematopoietic promoters), by phosphorylation-dependent ubiquitin-mediated degradation through SPOP and TRIM8 as E3 ligases opposed by the deubiquitinases USP19 and OTUD7A, and by functional interactions with CBP and STAT1 that regulate chromatin accessibility at target loci such as IDO1 [PMID:27431361, PMID:34060252, PMID:34329586, PMID:38816360]. Haploinsufficiency of FLI1 underlies defective thrombopoiesis in Paris-Trousseau syndrome, while the EWS-FLI1 fusion acts as an aberrant transcriptional activator driving Ewing sarcoma [PMID:28432223, PMID:7503813].\",\n  \"teleology\": [\n    {\n      \"year\": 1993,\n      \"claim\": \"Determining how the EWS-FLI1 fusion creates oncogenic transcriptional activity: the EWS N-terminal domain substitutes for the FLI1 N-terminal activation domain and de-represses the FLI1 C-terminal activation domain, establishing EWS-FLI1 as a gain-of-function transcriptional activator.\",\n      \"evidence\": \"Deletion mutagenesis and transient transfection reporter assays in cell lines\",\n      \"pmids\": [\"7503813\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Chromatin-level targets of EWS-FLI1 versus wild-type FLI1 not yet distinguished\",\n        \"No structural basis for how EWS NTD activates the C-terminal domain\"\n      ]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Addressing whether FLI1 cross-talks with nuclear receptor signaling: FLI1 and RARα reciprocally repress each other's transcriptional activity via an indirect bridging factor, not direct DNA-binding competition.\",\n      \"evidence\": \"Reporter assays, EMSA, and deletion mutagenesis in transfected cells\",\n      \"pmids\": [\"9444955\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Identity of the bridging factor mediating FLI1-RARα cross-repression unknown\",\n        \"No endogenous target gene validation\"\n      ]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Testing whether FLI1 overexpression is sufficient to block erythroid differentiation: FLI1 inhibits terminal erythroid differentiation and apoptosis while upregulating Bcl-2 and maintaining cyclin D2/D3, independently of EpoR signaling.\",\n      \"evidence\": \"Retroviral overexpression in primary avian erythroblasts with proliferation and differentiation assays\",\n      \"pmids\": [\"10102630\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Direct versus indirect transcriptional targets mediating anti-differentiation effects not resolved\",\n        \"Relevance to mammalian erythropoiesis not tested\"\n      ]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Establishing FLI1's in vivo requirement: Fli1-null mice die at E11.5 with hemorrhage, loss of vascular integrity, and downregulation of Tek/Tie-2, proving FLI1 is essential for vascular and megakaryocytic development.\",\n      \"evidence\": \"Targeted Fli1 null mutation in mice with phenotypic and molecular analysis\",\n      \"pmids\": [\"10981960\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether megakaryocyte versus endothelial defects are cell-autonomous was not resolved\",\n        \"Full set of direct FLI1 target genes in endothelium not defined\"\n      ]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Resolving the mechanism of erythroid–megakaryocytic fate choice: FLI1 and EKLF physically interact and reciprocally repress each other's lineage-specific promoters, with FLI1's ETS domain mediating repression of erythroid genes.\",\n      \"evidence\": \"Co-IP, GST pulldown, reporter assays, and Gal4 domain fusion analysis\",\n      \"pmids\": [\"12556498\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"In vivo validation of FLI1-EKLF antagonism at endogenous loci not shown\",\n        \"Stoichiometric balance between the two factors during lineage commitment not quantified\"\n      ]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Identifying FLI1 direct target genes in the endothelial/hematopoietic program: FLI1 binds conserved ETS sites in the LMO2 proximal promoter and regulates its expression in endothelial cells.\",\n      \"evidence\": \"ChIP in progenitor and endothelial cell lines, transgenic mouse enhancer analysis\",\n      \"pmids\": [\"15994290\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Functional consequence of FLI1 loss on LMO2-dependent programs not tested\",\n        \"Redundancy with Elf1 and Ets1 at this promoter not resolved\"\n      ]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Revealing Flightless-I (FLII) as a transcriptional coregulator: FLII coactivates nuclear receptor-mediated transcription and inhibits β-catenin/LEF1/TCF signaling by disrupting FLAP1–p300–β-catenin synergy.\",\n      \"evidence\": \"Co-IP, GST pulldown, reporter assays, and siRNA knockdown\",\n      \"pmids\": [\"16990252\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Endogenous chromatin targets of FLII coactivator function not mapped\",\n        \"Relative contribution of gelsolin-like versus LRR domain to coactivator activity unclear\"\n      ]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Defining the core hematopoietic gene-regulatory circuit: GATA2, FLI1, and SCL each bind the enhancers of the other two genes, forming a fully connected autoregulatory triad in the dorsal aorta and fetal liver.\",\n      \"evidence\": \"ChIP at defined enhancers (Fli1+12, Gata2−3, Scl+19) and transgenic enhancer analysis\",\n      \"pmids\": [\"17962413\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Temporal order of circuit establishment not resolved\",\n        \"Whether the triad is sufficient to initiate hematopoietic fate not tested by gain-of-function\"\n      ]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Extending FLI1 function to lymphoid development: the C-terminal activation domain of FLI1 is required for normal follicular B cell numbers, and its truncation alters expression of Igα, Pax-5, E2A, and Id genes in a cell-intrinsic manner.\",\n      \"evidence\": \"Fli1(ΔCTA) knock-in mice with bone marrow reconstitution and flow cytometry\",\n      \"pmids\": [\"18641300\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Direct versus indirect transcriptional targets in B cells not distinguished by ChIP\",\n        \"Whether full FLI1 knockout produces a more severe lymphoid phenotype not tested\"\n      ]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Demonstrating FLII's role in tissue remodeling: FLII dosage modulates dermal-epidermal blistering severity, integrin and ColVII expression, and TGF-β1/Smad2/3 signaling in an autoimmune skin disease model.\",\n      \"evidence\": \"Flii-overexpressing and Flii+/− mice in EBA model, collagen gel contraction assays\",\n      \"pmids\": [\"21984127\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Molecular mechanism by which FLII regulates TGF-β1 signaling not defined\",\n        \"Whether FLII acts in fibroblasts, keratinocytes, or both not resolved\"\n      ]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Uncovering a phosphorylation–miRNA feedback loop: loss of FLI1 DNA-binding activity correlates with increased FLI1 phosphorylation, and de-repression of miR-145 creates an autoregulatory loop that further downregulates FLI1.\",\n      \"evidence\": \"EMSA, ChIP, drug treatment with phosphorylation analysis, in vivo leukemia model\",\n      \"pmids\": [\"22829238\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Kinase responsible for inhibitory FLI1 phosphorylation not identified\",\n        \"Whether miR-145 loop operates during normal hematopoiesis unknown\"\n      ]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Establishing FLI1 positive autoregulation in endothelium: FLI1 binds its own promoter/enhancer ETS sites to sustain endothelial gene expression after the initial activator Etv2 is silenced at midgestation.\",\n      \"evidence\": \"ChIP and loss/gain-of-function in vivo in mice\",\n      \"pmids\": [\"24727028\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether other ETS factors compensate for FLI1 autoregulation not addressed\",\n        \"Epigenetic mechanism of promoter maintenance not explored\"\n      ]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Providing structural insight into FLI1 dimerization: crystal structures revealed a helix-swapped homodimer interface in the ETS/DBD domain mediated by Phe362; F362A mutation disrupts dimerization without affecting DNA binding or fold.\",\n      \"evidence\": \"X-ray crystallography, analytical ultracentrifugation, site-directed mutagenesis\",\n      \"pmids\": [\"26618620\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Functional consequence of dimerization for transcriptional activity or target selection in vivo unknown\",\n        \"Whether EWS-FLI1 retains this dimerization interface not tested\"\n      ]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Defining acetylation as a regulatory PTM for FLI1: p300/CBP and PCAF acetylate FLI1, and this modification decreases FLI1 transactivation at hematopoietic promoters such as G-CSF, while an acetylation-site mutant shows enhanced activity.\",\n      \"evidence\": \"In vitro acetylation assays, ChIP, reporter assays with acetylation-site mutagenesis\",\n      \"pmids\": [\"27431361\", \"22973553\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Opposing effects reported for EWS-FLI1 versus wild-type FLI1 acetylation not reconciled\",\n        \"In vivo stoichiometry of FLI1 acetylation not measured\"\n      ]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Connecting FLI1 to immune tolerance and disease: epithelial Fli1 knockout causes fibrosis and autoimmunity via direct regulation of Aire, and FLI1 haploinsufficiency impairs thrombopoiesis in Paris-Trousseau syndrome through reduced megakaryocyte yield.\",\n      \"evidence\": \"K14-Cre conditional KO mice with ChIP; iPSC-derived megakaryocytes from Paris-Trousseau patients and FLI1+/− iPSCs with in vivo platelet infusion\",\n      \"pmids\": [\"28232470\", \"28432223\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Full spectrum of epithelial FLI1 targets beyond Aire not defined\",\n        \"Whether FLI1 gene therapy can rescue Paris-Trousseau platelet defects in vivo not tested\"\n      ]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Establishing FLI1's role in maintaining endothelial identity: combined loss of ERG and FLI1 triggers endothelial-to-mesenchymal transition with genome-wide epigenetic reprogramming, identifying miR-126 as a partially protective downstream target.\",\n      \"evidence\": \"siRNA knockdown in endothelial cells with genome-wide epigenomic and transcriptomic profiling\",\n      \"pmids\": [\"30500808\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Individual contribution of FLI1 versus ERG to EndMT not cleanly separated\",\n        \"Whether EndMT is reversible upon FLI1 restoration not tested\"\n      ]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Defining the ubiquitin-proteasome axis controlling EWS-FLI1 stability: TRIM8 and SPOP serve as E3 ligases that ubiquitinate EWS-FLI1 for degradation (SPOP dependent on CK1-mediated phosphorylation of a VTSSS degron), while OTUD7A and USP19 are opposing deubiquitinases that stabilize the fusion protein.\",\n      \"evidence\": \"CRISPR screens, ubiquitination/deubiquitination biochemistry, phosphorylation assays, xenograft models\",\n      \"pmids\": [\"34329586\", \"34060252\", \"30700749\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether wild-type FLI1 is regulated by the same E3/DUB machinery not fully resolved\",\n        \"Structural basis of SPOP degron recognition in FLI1 not determined\"\n      ]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Revealing FLI1 as a cell-intrinsic checkpoint in NK cell memory: STAT5 induces FLI1, which upregulates Bim to limit memory precursor NK cell formation during viral infection.\",\n      \"evidence\": \"scRNA-seq, Fli1-deficient mice, ex vivo STAT5 stimulation, epigenetic profiling\",\n      \"pmids\": [\"35288713\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether FLI1 directly binds Bim regulatory regions not shown by ChIP\",\n        \"Applicability to human NK cell biology not tested\"\n      ]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Linking FLI1 to immune evasion: FLI1 orchestrates CBP and STAT1 expression to open chromatin at the IDO1 locus upon IFN-γ stimulation, driving kynurenine production that promotes CD8+ T cell exhaustion and Treg differentiation in tumors.\",\n      \"evidence\": \"ChIP, gene expression, pharmacological FLI1 inhibition, T cell functional assays, in vivo tumor models\",\n      \"pmids\": [\"38816360\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether FLI1 directly binds CBP and STAT1 promoters versus acting indirectly not fully resolved\",\n        \"Tumor-type generalizability of the FLI1–IDO1 axis not established\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the functional significance of FLI1 homodimerization for target gene selection in vivo, the identity of kinases governing inhibitory FLI1 phosphorylation during normal hematopoiesis, and whether the SPOP/TRIM8 ubiquitin ligase machinery controls wild-type FLI1 turnover outside the Ewing sarcoma context.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"No in vivo functional data on FLI1 homodimerization\",\n        \"Kinase for inhibitory phosphorylation not identified\",\n        \"Wild-type FLI1 ubiquitin-dependent turnover mechanism not characterized\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [1, 2, 13, 14, 24]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 1, 2, 3, 4, 8, 10, 11, 12, 15, 16, 22]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [1, 2, 3, 4, 13, 14, 15]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [1, 2, 3, 4, 8, 10, 11, 12, 15, 16, 22]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [0, 4, 17]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [9, 10, 21, 22]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [3, 5, 25]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [19, 20, 23]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"EKLF\",\n      \"GATA2\",\n      \"SCL\",\n      \"CBP\",\n      \"STAT1\",\n      \"SPOP\",\n      \"TRIM8\",\n      \"OTUD7A\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"FLII (Protein flightless-1 homolog) is an actin-remodeling protein that functions as a transcriptional coactivator for nuclear receptor targets and as a repressor of Wnt/β-catenin signaling by disrupting the FLAP1–p300–β-catenin complex [PMID:16990252]. FLII regulates skin integrity and blistering severity in epidermolysis bullosa: overexpression exacerbates blistering in murine collagen VII models, while reduced FLII expression improves collagen VII production, elevates integrin expression, and attenuates TGF-β1/Smad2/3-driven fibrosis [PMID:21984127].\",\n  \"teleology\": [\n    {\n      \"year\": 2006,\n      \"claim\": \"Establishing that FLII operates as a dual transcriptional regulator — coactivating nuclear receptor targets while suppressing Wnt/β-catenin/LEF1/TCF-dependent transcription through disruption of the FLAP1–p300–β-catenin complex — answered how a single gelsolin-family protein could modulate both nuclear receptor and Wnt signaling outputs.\",\n      \"evidence\": \"Transient transfection reporter assays, co-immunoprecipitation, GST pull-down, and siRNA knockdown of FLAP1 in mammalian cell lines\",\n      \"pmids\": [\"16990252\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"No structural or in vivo validation of the FLII–FLAP1–p300–β-catenin disruption mechanism\",\n        \"Endogenous chromatin context and genome-wide target genes of FLII transcriptional regulation are undefined\",\n        \"Whether FLII actin-binding and transcriptional activities are coupled or independent remains unresolved\"\n      ]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Demonstrating that FLII dosage directly controls skin blistering severity in epidermolysis bullosa models — with overexpression worsening and haploinsufficiency ameliorating disease through modulation of collagen VII, integrin expression, and TGF-β1/Smad2/3 signaling — established FLII as a pathogenic mediator in EB and linked its function to fibrotic remodeling in vivo.\",\n      \"evidence\": \"Flii allelic series (overexpression and heterozygous knockout) in autoimmune collagen VII EBA and ColVII hypomorphic mouse models, collagen gel contraction assays, immunofluorescence, and Western blot\",\n      \"pmids\": [\"21984127\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Direct molecular mechanism by which FLII regulates TGF-β1/Smad2/3 signaling is not delineated\",\n        \"Whether FLII transcriptional co-regulation (Wnt/nuclear receptor) contributes to the blistering phenotype is untested\",\n        \"Therapeutic applicability of FLII reduction in human epidermolysis bullosa has not been demonstrated\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The relationship between FLII's actin-remodeling activity, its transcriptional co-regulatory roles, and its in vivo control of skin integrity remains mechanistically unintegrated — it is unknown whether these represent a single pathway or separable functions.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"No domain-specific mutations separating actin-binding from transcriptional functions have been tested in vivo\",\n        \"Genome-wide transcriptional targets of FLII in skin and other tissues are uncharacterized\",\n        \"Structural basis for FLII interaction with FLAP1, p300, and β-catenin is unknown\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0]},\n      {\"term_id\": \"GO:0008092\", \"supporting_discovery_ids\": [1]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 1]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [1]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"FLAP1\", \"CTNNB1\", \"EP300\", \"GRIP1\"],\n    \"other_free_text\": []\n  }\n}\n```"}